Behçet’s Disease Treatment Market Share & Growth [2032]
Behçet’s Disease Treatment Market Share & Growth [2032]
Segments - by Treatment Method (Medication, Physical Therapy, Surgery, Lifestyle Management), by Drug Class (Cortico steroids, Immuno suppressants, Immuno modulators, Biologics, Others), by Route Of Administration (Oral, Intravenous, Topical), by Patient Age (Pediatric, Adult, Geriatric), by Distribution Channel (Pharmacies, Online, Others)
Upcoming
| Report ID :HC-7109
| 5.1 Rating
| 90 Reviews
| 300 Pages
| Format :
Report Description
Behçet’s Disease Treatment Market Outlook 2032
The global Behçet’s disease treatment market size was USD 1.6 Billion in 2023 and is likely to reach USD 2.5 Billion by 2032, expanding at a CAGR of 5.16% during 2024–2032. The market growth is attributed to the increasing number of cases across the globe.
Behçet’s disease or Behçet’s syndrome is a rare chronic autoimmune disorder caused by the inflammation of blood vessels throughout the human body. It affects multiple systems, causing symptoms such as oral ulcers, skin lesions, and eye inflammation.
According to the National Institutes of Health (NIH), the prevalence of Behçet’s disease is estimated to be between 0.33 to 5.2 cases per 100,000 individuals in North America, and up to 20 cases per 100,000 in Asia Pacific and the Middle East. Turkey reportedly has 420 cases per 100,000 individuals.
The exact cause of Behçet’s disease is unknown, althoughit is suspected to have a genetic constituent. Certain human leukocyte antigen (HLA) alleles are associated with an increased susceptibility to the disease. The possibility of identifying individuals with a genetic predisposition to the illness is stronger than before as genetic testing becomes accessible.
Behçet’s Disease TreatmentMarket Dynamics
Major Drivers
Rapid improvement in the field of diagnostics is a major driver in the market. Researchers are studying and understanding the epidemiology of Behçet’s disease. The awareness of rare diseases has risen due to the increasing cases globally.
Improved diagnostic methodologies are being used to diagnose patients. The genetic predisposition and environmental factors, especially among the countries along the Silk Road, have led to a high incidence rate and a rising demand for effective treatment.
Advancements in medical technology and pharmaceutical research are driving the market. Pharmaceutical companies are focusing on developing drugs and other treatment methods. The development of biologics and immunomodulators, which offer a target and effective management of affected parts, was a breakthrough in treating Behçet’s disease. Other therapeutic options were introduced to lessen patient pain and have a holistic approach to the illness.
There is growing awareness about rare diseases amongst people and healthcare professionals alike, which drive the market. Educational campaigns and spearheaded initiatives from governmental and non-government organizations have made the general public aware of rare afflictions.
The information about the condition, symptoms, and treatments is widely available. Increasing healthcare budgets have led to fruitful endeavors by organizations and researchers to find a permanent cure.
The post-pandemic environment has led to enhanced disease management systems in place worldwide, boosting the market. There are a growing number of specialized centers dedicated to rare diseases globally, coupled with the expertise of healthcare practitioners.
Such centers provide a focused environment for diagnosing and treating rare conditions, including Behçet’s disease. Specialists provide personalized treatment plans, enhancing the quality of care received by the patients.
Existing Restraints
There is a significant lack of standardized treatment guidelines that hinder the market. The absence of universally accepted treatment protocols leads to variations in care and inconsistency across different patient outcomes.
The complex nature of the disease and wide-ranging symptoms mean that different healthcare providers utilize different approaches for treatment, resulting in delays and suboptimal care. Without a standardized guideline, patients do not get appropriate therapy, which causes improper management of symptoms, or worsening of the condition. This lack of uniformity creates huge uncertainties and challenges.
The high risk of side effects is a crucial market restraint. Long-term use of medicines such as corticosteroids and immunosuppressants has been linked to organ toxicity, heightened risk of cancer, fatigue, muscle cramps, nausea, vomiting, diarrhea, and in some cases, low blood count, edema, severe liver problems, &congestive heart failure.
Additionally, the combination of small molecule-based drugs leads to myelosuppression. Immuno suppressants augment the risk of infections necessitating close patient monitoring, a resource-draining and time-intensive burden on healthcare systems with limited capabilities.
Behçet’s disease is difficult to diagnose, which obstructs the market. There are no biological markers or standardized tests to detect Behçet’s disease, with physicians usually relying on indications and symptoms.
Early detection is close to impossible as each patient manifests symptoms differently. Most symptoms of the illness, such as mouth sores, are frequently caused by different infections, making the diagnosis hard. This multi fariousness complicates clinical trials. The usual diagnosis is at least three instances of mouth sores in a year, as well as two genital sores, eye irritation, skin lesions or skin sores, and appositive skin prick test.
Emerging Opportunities
R&D investments have increased after the COVID-19 pandemic, which is expected to create lucrative opportunities for the market during the forecast period. Big pharmaceutical companies are developing new treatments with improvedefficacy and fewer side effects.
The introduction of biologics and advanced immuno modulators is a sign of significant progress. Corporates and research institutions are collaborating to make efficient use of manpower and progress at a rapid pace. New drugs are being made and treatment protocols are being improved as the approach to treatment becomes multidisciplinary. Jak inhibitors and IL-6 inhibitors are being used for targeted therapies to modulate immune system pathways.
The growing demand for personalized medicine is likely to create chances for market players. Digital health platforms offering services such as patient monitoring and engagement are being developed. Telemedicine and remote monitoring are the new buzzwords in the market. Personalized medicine offers tailored treatments for individuals based on their genetic makeup and clinical profiles.
This avoids the lengthy and exhaustive trial-and-error processes of traditional medicine. Precision medicine reduces the risk of side effects by identifying appropriate drugs for underlying conditions. Innovations in pharmacotherapy and personalized medicines are results of increasing interest in precision medicine, permitting efficient treatment for each patient.
Scope of the Behçet's Disease Treatment Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Behçet’s Disease Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017 -2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
Treatment Method (Medication, Physical Therapy, Surgery, and Lifestyle Management), Drug Class(Cortico steroids, Immuno suppressants,Immuno modulators, Biologics, and others), Route of Administration (Oral, Intravenous, and Topical), Patient Age (Pediatric, Adult, and Geriatric), and Distribution Channel (Pharmacies, Online, and Others) |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
AbbVie Inc.; Amgen Inc.; AstraZeneca plc; Bayer AG; Biogen Inc.; Celgene Corporation (subsidiary of Bristol-Myers Squibb); Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Takeda; Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; UCB S.A.; and Vertex Pharmaceuticals Incorporated |
Behçet’s Disease TreatmentMarket Segment Insights
Treatment Method Segment Analysis
Based on the treatment method, the Behçet’s disease treatment market is divided into medication, physical therapy, surgery, and lifestyle management. The medication segment holds a major share of the market, due to its significant role in managing symptoms and preventing flare-ups. Medications are a vital aspect in maintaining the quality of life of patients suffering from Behçet’s disease.
The main medications used to treat the disease include corticosteroids, immuno suppressants, and colchine. The choice of medication depends on the patient’s clinical manifestations of Behçet’s disease. Medications act quickly, making them one of the most potent forms of treatment to suppress the symptoms and relieve patient pain.
The lifestyle management segment is expected to expand at a significant growth rate in the coming years, owing to the sedentary lifestyles of today, coupled with unhealthy eating habits, increased stress levels, and dangerous amounts of exposure to pollutants and additives.
Lifestyle management becomes an integral part of the treatment process as clinical treatments consider a multidisciplinary and holistic approach to the disease. Alternative forms of therapy such as yoga, ayurveda, and tai chi are gaining popularity in occidental countries due to their lifestyle regimen and diet.
Drug Class Segment Analysis
On the basis of drug class, the global market is segregated into corticosteroids, immunosuppressants, immunomodulators, biologics, and others. The corticosteroids segment holds a large market share due to their widespread use for treatment.
Effective in reducing inflammation and flare-ups, corticosteroids are prescribed for acute treatment phases, usually for ozmunosuppressants, or biotherapy. Corticosteroids are known for their rapid action, althoughtheir long-term use is linked with serious side effects, making alternative treatments necessary.
The biologics segment is anticipated to expandat a substantial CAGR during the forecast period, owing to their treatment potential. Biologics are drugs that are designed to target specific components of the immune system. Healthcare professionals favor targeted treatments due to reduced side effects, improved effectiveness, personalized medical dosage, and improvedquality of life for patients.
Route of Administration Segment Analysis
In terms of route of administration, the Behçet’s disease treatment market is segmented into oral, intravenous, and topical. The oral segment leads the market due to it being the most common way to medicate a patient. Ingesting pills orally is convenient and easy to use.
Many corticosteroids and immuno suppressants are available in oral formulations. Additionally, medications are easy to store and transport in the form of pills and tablets. Patients and healthcare providers are overwhelmingly in favor of the oral route,owing to the simple and non-invasive mode of administration.
The intravenous segment holds a significant market share. The segment consists of biologics and some immunosuppressants administered through injections. They are used in severe cases with a need for rapid action.
Intravenous administration is chosen for precise dosing and quicker therapeutic effects. Injections are preferred in clinical settings, as their efficacy in managing severe symptoms makes them indispensable. However, the route is often inconvenient and painful for patients due to the procedures involved.
The topical segment is projected to register a robust growth rate during the assessment years, owing to their efficacy on localized symptoms such as skin lesions and oral ulcers. Topical corticosteroids and immunomodulators effectively manage symptoms with minimal systemic side effects.
The mode of administration is incredibly advantageous for patients unable to bear oral or intravenous procedures. Topical routes, however, are considered supplementary and used in conjunction with other forms of treatment.
Patient Age Segment Analysis
Based on patient age, the global market is divided into pediatric, adult, and geriatric. The adult segment generated a major revenue share of the market in 2023, owing to the primary patient age segment being young adults between 20 and 40 years old, with the mean age at onset typically falling between 25 and 30 years old.
While both sexes are affected, some studies suggest a slightly higher prevalence in males, particularly in certain ethnic groups. Adults require advanced therapeutic options as they face complex disease manifestations.
The pediatric segment refers to people who are 21 years old or under at the time of diagnosis or treatment. The segment is particularly essential due to cases where Behçet’s disease has an early onset. Patients in the pediatric age group need tailored treatments that address their unique developmental needs.
The geriatric segment is becoming increasingly relevant in the market as age-related complications arise. Geriatrics need specialized care as the disease leads to complications in vascular, neurological, and/or ocular systems.
Management of the symptoms is complex due to the age, requiring tailored therapies that minimize side effects and interactions with any other drugs that they are taking.
Distribution Channel Segment Analysis
Based on distribution channels, the global market is segregated into pharmacies, online, and others. The pharmacies segment held a large market share in 2023, due to the pharmacy facilities being primary distribution centers for oral, topical, and intravenous medication. Pharmacies provide easy access and convenience to the general public.
Hospital pharmacies ensure patients have immediate access to necessary medicine during their visit. They collaborate with healthcare providers to manage the medication regimen required for treatment. Retail pharmacies stock a wide range of medications, making them a go-to option for patients.
Specialty pharmacies provide medications required for complex conditions as well as chronic disease management. Additionally, they provide services such as patient education and medication management.
The online segment is anticipated to expandat a substantial CAGR during the forecast period, gaining traction due to the growth of e-commerce and the convenience offered by shopping from the comfort of home. Many online platforms offer home delivery, subscription-based pricing models, competitive pricing, and discount offers & coupons, which are a financial benefit for long-time treatments. Increasing internet and smartphone usage isdriving the segment.
Regional Outlook
In terms of region, the global Behçet’s disease treatment market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa.
Asia Pacific held a major market share in 2023, due to the prevalence of the disease in the region. The high number of incidents has led to a growing demand for effective treatments. Behçet’s disease has a strong genetic component, due to which the population along the Silk Road is susceptible to the condition.
Sedentary lifestyles, including unhealthy diet, high stress levels, and exposure to pollutants, are potential cases for exacerbation. Soaring numbers in Turkey, Japan, and China have made regional governments invest in improving healthcare infrastructures. Many government initiatives are aimed at improving healthcare accessibility and increasing awareness about rare diseases.
The market in North America is projected to grow at a significant pace in the coming years, owing to the presence of advanced healthcare systems and R&D infrastructure. In the countries of the US and Canada, a key portion of the market is occupied by ongoing clinical trials and research initiatives. The presence of major pharmaceutical industries, companies, and research institutions in the region is expected to boost the regional markets in the coming years.
Segments
The Behçet’s disease treatment market has been segmented on the basis of
Treatment Method
- Medication
- Physical Therapy
- Surgery
- Lifestyle Management
Drug Class
- Corticosteroids
- Immunosuppressants
- Immunomodulators
- Biologics
Route of Administration
- Oral
- Intravenous
- Topical
Patient Age
- Pediatric
- Adult
- Geriatric
Distribution Channel
- Pharmacies
- Online
- Others
Region
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
Key Players
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Biogen Inc.
- Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- TakedaPharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Vertex Pharmaceuticals Incorporated
Competitive Landscape
The global Behçet’s disease treatment market is highly competitive, with several major pharmaceutical companies developing and marketing medications for a condition that is rare, chronic, and often debilitating. The market includes biologics, corticosteroids, and immunosuppressants used alongside supportive treatments aimed to mitigate the symptoms.
Some of the well-known key players competing in the market include Novartis, Bristol-Myers Squibb (BMS), Johnson&Johnson, and UCB. Novartis has a strong portfolio in immunology and developed several biologics, including IL-6.
Bristol Myers Squibb is known for immune-oncology products, while UCB has a strong market presence with Certolizumab pegol (Cimzia)being explored for various inflammatory diseases. The market dynamics currently favor trends such as the use and production of biologics and the evolution of personalized medication.
Major market players are intensifying their efforts to improve therapeutic options for patients. Ongoing clinical trials and partnerships are expected to lead to new treatment avenues and the expansion of the use of existing drugs, strengthening the growing market.
-
In February 2024, Soligenix, Inc. announced the formation of a medical advisory board to provide medical/clinical strategic guidance for the clinical development of SGC945 (dusquetide) for the treatment of Behçet's disease. The US Food and Drug Administration had granted Fast Track designation for dusquetide in the treatment of oral lesions of Behçet's disease.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Behçet’s Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Behçet’s Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Behçet’s Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Behçet’s Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Behçet’s Disease Treatment Market Size & Forecast, 2023-2032
4.5.1 Behçet’s Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Behçet’s Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Behçet’s Disease Treatment Market Analysis and Forecast By Treatment Method
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Treatment Method
5.1.2 Basis Point Share (BPS) Analysis By Treatment Method
5.1.3 Absolute $ Opportunity Assessment By Treatment Method
5.2 Behçet’s Disease Treatment Market Size Forecast By Treatment Method
5.2.1 Medication
5.2.2 Physical Therapy
5.2.3 Surgery
5.2.4 Lifestyle Management
5.3 Market Attractiveness Analysis By Treatment Method
Chapter 6 Global Behçet’s Disease Treatment Market Analysis and Forecast By Drug Class
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Drug Class
6.1.2 Basis Point Share (BPS) Analysis By Drug Class
6.1.3 Absolute $ Opportunity Assessment By Drug Class
6.2 Behçet’s Disease Treatment Market Size Forecast By Drug Class
6.2.1 Cortico steroids
6.2.2 Immuno suppressants
6.2.3 Immuno modulators
6.2.4 Biologics
6.2.5 Others
6.3 Market Attractiveness Analysis By Drug Class
Chapter 7 Global Behçet’s Disease Treatment Market Analysis and Forecast By Route Of Administration
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Route Of Administration
7.1.2 Basis Point Share (BPS) Analysis By Route Of Administration
7.1.3 Absolute $ Opportunity Assessment By Route Of Administration
7.2 Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
7.2.1 Oral
7.2.2 Intravenous
7.2.3 Topical
7.3 Market Attractiveness Analysis By Route Of Administration
Chapter 8 Global Behçet’s Disease Treatment Market Analysis and Forecast By Patient Age
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By Patient Age
8.1.2 Basis Point Share (BPS) Analysis By Patient Age
8.1.3 Absolute $ Opportunity Assessment By Patient Age
8.2 Behçet’s Disease Treatment Market Size Forecast By Patient Age
8.2.1 Pediatric
8.2.2 Adult
8.2.3 Geriatric
8.3 Market Attractiveness Analysis By Patient Age
Chapter 9 Global Behçet’s Disease Treatment Market Analysis and Forecast By Distribution Channel
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
9.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
9.1.3 Absolute $ Opportunity Assessment By Distribution Channel
9.2 Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
9.2.1 Pharmacies
9.2.2 Online
9.2.3 Others
9.3 Market Attractiveness Analysis By Distribution Channel
Chapter 10 Global Behçet’s Disease Treatment Market Analysis and Forecast by Region
10.1 Introduction
10.1.1 Key Market Trends & Growth Opportunities By Region
10.1.2 Basis Point Share (BPS) Analysis By Region
10.1.3 Absolute $ Opportunity Assessment By Region
10.2 Behçet’s Disease Treatment Market Size Forecast By Region
10.2.1 North America
10.2.2 Europe
10.2.3 Asia Pacific
10.2.4 Latin America
10.2.5 Middle East & Africa (MEA)
10.3 Market Attractiveness Analysis By Region
Chapter 11 Coronavirus Disease (COVID-19) Impact
11.1 Introduction
11.2 Current & Future Impact Analysis
11.3 Economic Impact Analysis
11.4 Government Policies
11.5 Investment Scenario
Chapter 12 North America Behçet’s Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 North America Behçet’s Disease Treatment Market Size Forecast by Country
12.2.1 U.S.
12.2.2 Canada
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 North America Behçet’s Disease Treatment Market Size Forecast By Treatment Method
12.6.1 Medication
12.6.2 Physical Therapy
12.6.3 Surgery
12.6.4 Lifestyle Management
12.7 Basis Point Share (BPS) Analysis By Treatment Method
12.8 Absolute $ Opportunity Assessment By Treatment Method
12.9 Market Attractiveness Analysis By Treatment Method
12.10 North America Behçet’s Disease Treatment Market Size Forecast By Drug Class
12.10.1 Cortico steroids
12.10.2 Immuno suppressants
12.10.3 Immuno modulators
12.10.4 Biologics
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis By Drug Class
12.12 Absolute $ Opportunity Assessment By Drug Class
12.13 Market Attractiveness Analysis By Drug Class
12.14 North America Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
12.14.1 Oral
12.14.2 Intravenous
12.14.3 Topical
12.15 Basis Point Share (BPS) Analysis By Route Of Administration
12.16 Absolute $ Opportunity Assessment By Route Of Administration
12.17 Market Attractiveness Analysis By Route Of Administration
12.18 North America Behçet’s Disease Treatment Market Size Forecast By Patient Age
12.18.1 Pediatric
12.18.2 Adult
12.18.3 Geriatric
12.19 Basis Point Share (BPS) Analysis By Patient Age
12.20 Absolute $ Opportunity Assessment By Patient Age
12.21 Market Attractiveness Analysis By Patient Age
12.22 North America Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
12.22.1 Pharmacies
12.22.2 Online
12.22.3 Others
12.23 Basis Point Share (BPS) Analysis By Distribution Channel
12.24 Absolute $ Opportunity Assessment By Distribution Channel
12.25 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Europe Behçet’s Disease Treatment Analysis and Forecast
13.1 Introduction
13.2 Europe Behçet’s Disease Treatment Market Size Forecast by Country
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 U.K.
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Europe Behçet’s Disease Treatment Market Size Forecast By Treatment Method
13.6.1 Medication
13.6.2 Physical Therapy
13.6.3 Surgery
13.6.4 Lifestyle Management
13.7 Basis Point Share (BPS) Analysis By Treatment Method
13.8 Absolute $ Opportunity Assessment By Treatment Method
13.9 Market Attractiveness Analysis By Treatment Method
13.10 Europe Behçet’s Disease Treatment Market Size Forecast By Drug Class
13.10.1 Cortico steroids
13.10.2 Immuno suppressants
13.10.3 Immuno modulators
13.10.4 Biologics
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis By Drug Class
13.12 Absolute $ Opportunity Assessment By Drug Class
13.13 Market Attractiveness Analysis By Drug Class
13.14 Europe Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
13.14.1 Oral
13.14.2 Intravenous
13.14.3 Topical
13.15 Basis Point Share (BPS) Analysis By Route Of Administration
13.16 Absolute $ Opportunity Assessment By Route Of Administration
13.17 Market Attractiveness Analysis By Route Of Administration
13.18 Europe Behçet’s Disease Treatment Market Size Forecast By Patient Age
13.18.1 Pediatric
13.18.2 Adult
13.18.3 Geriatric
13.19 Basis Point Share (BPS) Analysis By Patient Age
13.20 Absolute $ Opportunity Assessment By Patient Age
13.21 Market Attractiveness Analysis By Patient Age
13.22 Europe Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
13.22.1 Pharmacies
13.22.2 Online
13.22.3 Others
13.23 Basis Point Share (BPS) Analysis By Distribution Channel
13.24 Absolute $ Opportunity Assessment By Distribution Channel
13.25 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Asia Pacific Behçet’s Disease Treatment Analysis and Forecast
14.1 Introduction
14.2 Asia Pacific Behçet’s Disease Treatment Market Size Forecast by Country
14.2.1 China
14.2.2 Japan
14.2.3 South Korea
14.2.4 India
14.2.5 Australia
14.2.6 South East Asia (SEA)
14.2.7 Rest of Asia Pacific (APAC)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Asia Pacific Behçet’s Disease Treatment Market Size Forecast By Treatment Method
14.6.1 Medication
14.6.2 Physical Therapy
14.6.3 Surgery
14.6.4 Lifestyle Management
14.7 Basis Point Share (BPS) Analysis By Treatment Method
14.8 Absolute $ Opportunity Assessment By Treatment Method
14.9 Market Attractiveness Analysis By Treatment Method
14.10 Asia Pacific Behçet’s Disease Treatment Market Size Forecast By Drug Class
14.10.1 Cortico steroids
14.10.2 Immuno suppressants
14.10.3 Immuno modulators
14.10.4 Biologics
14.10.5 Others
14.11 Basis Point Share (BPS) Analysis By Drug Class
14.12 Absolute $ Opportunity Assessment By Drug Class
14.13 Market Attractiveness Analysis By Drug Class
14.14 Asia Pacific Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
14.14.1 Oral
14.14.2 Intravenous
14.14.3 Topical
14.15 Basis Point Share (BPS) Analysis By Route Of Administration
14.16 Absolute $ Opportunity Assessment By Route Of Administration
14.17 Market Attractiveness Analysis By Route Of Administration
14.18 Asia Pacific Behçet’s Disease Treatment Market Size Forecast By Patient Age
14.18.1 Pediatric
14.18.2 Adult
14.18.3 Geriatric
14.19 Basis Point Share (BPS) Analysis By Patient Age
14.20 Absolute $ Opportunity Assessment By Patient Age
14.21 Market Attractiveness Analysis By Patient Age
14.22 Asia Pacific Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
14.22.1 Pharmacies
14.22.2 Online
14.22.3 Others
14.23 Basis Point Share (BPS) Analysis By Distribution Channel
14.24 Absolute $ Opportunity Assessment By Distribution Channel
14.25 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Latin America Behçet’s Disease Treatment Analysis and Forecast
15.1 Introduction
15.2 Latin America Behçet’s Disease Treatment Market Size Forecast by Country
15.2.1 Brazil
15.2.2 Mexico
15.2.3 Rest of Latin America (LATAM)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Latin America Behçet’s Disease Treatment Market Size Forecast By Treatment Method
15.6.1 Medication
15.6.2 Physical Therapy
15.6.3 Surgery
15.6.4 Lifestyle Management
15.7 Basis Point Share (BPS) Analysis By Treatment Method
15.8 Absolute $ Opportunity Assessment By Treatment Method
15.9 Market Attractiveness Analysis By Treatment Method
15.10 Latin America Behçet’s Disease Treatment Market Size Forecast By Drug Class
15.10.1 Cortico steroids
15.10.2 Immuno suppressants
15.10.3 Immuno modulators
15.10.4 Biologics
15.10.5 Others
15.11 Basis Point Share (BPS) Analysis By Drug Class
15.12 Absolute $ Opportunity Assessment By Drug Class
15.13 Market Attractiveness Analysis By Drug Class
15.14 Latin America Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
15.14.1 Oral
15.14.2 Intravenous
15.14.3 Topical
15.15 Basis Point Share (BPS) Analysis By Route Of Administration
15.16 Absolute $ Opportunity Assessment By Route Of Administration
15.17 Market Attractiveness Analysis By Route Of Administration
15.18 Latin America Behçet’s Disease Treatment Market Size Forecast By Patient Age
15.18.1 Pediatric
15.18.2 Adult
15.18.3 Geriatric
15.19 Basis Point Share (BPS) Analysis By Patient Age
15.20 Absolute $ Opportunity Assessment By Patient Age
15.21 Market Attractiveness Analysis By Patient Age
15.22 Latin America Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
15.22.1 Pharmacies
15.22.2 Online
15.22.3 Others
15.23 Basis Point Share (BPS) Analysis By Distribution Channel
15.24 Absolute $ Opportunity Assessment By Distribution Channel
15.25 Market Attractiveness Analysis By Distribution Channel
Chapter 16 Middle East & Africa (MEA) Behçet’s Disease Treatment Analysis and Forecast
16.1 Introduction
16.2 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast by Country
16.2.1 Saudi Arabia
16.2.2 South Africa
16.2.3 UAE
16.2.4 Rest of Middle East & Africa (MEA)
16.3 Basis Point Share (BPS) Analysis by Country
16.4 Absolute $ Opportunity Assessment by Country
16.5 Market Attractiveness Analysis by Country
16.6 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast By Treatment Method
16.6.1 Medication
16.6.2 Physical Therapy
16.6.3 Surgery
16.6.4 Lifestyle Management
16.7 Basis Point Share (BPS) Analysis By Treatment Method
16.8 Absolute $ Opportunity Assessment By Treatment Method
16.9 Market Attractiveness Analysis By Treatment Method
16.10 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast By Drug Class
16.10.1 Cortico steroids
16.10.2 Immuno suppressants
16.10.3 Immuno modulators
16.10.4 Biologics
16.10.5 Others
16.11 Basis Point Share (BPS) Analysis By Drug Class
16.12 Absolute $ Opportunity Assessment By Drug Class
16.13 Market Attractiveness Analysis By Drug Class
16.14 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast By Route Of Administration
16.14.1 Oral
16.14.2 Intravenous
16.14.3 Topical
16.15 Basis Point Share (BPS) Analysis By Route Of Administration
16.16 Absolute $ Opportunity Assessment By Route Of Administration
16.17 Market Attractiveness Analysis By Route Of Administration
16.18 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast By Patient Age
16.18.1 Pediatric
16.18.2 Adult
16.18.3 Geriatric
16.19 Basis Point Share (BPS) Analysis By Patient Age
16.20 Absolute $ Opportunity Assessment By Patient Age
16.21 Market Attractiveness Analysis By Patient Age
16.22 Middle East & Africa (MEA) Behçet’s Disease Treatment Market Size Forecast By Distribution Channel
16.22.1 Pharmacies
16.22.2 Online
16.22.3 Others
16.23 Basis Point Share (BPS) Analysis By Distribution Channel
16.24 Absolute $ Opportunity Assessment By Distribution Channel
16.25 Market Attractiveness Analysis By Distribution Channel
Chapter 17 Competition Landscape
17.1 Behçet’s Disease Treatment Market: Competitive Dashboard
17.2 Global Behçet’s Disease Treatment Market: Market Share Analysis, 2023
17.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
17.3.1 AbbVie Inc. Amgen Inc. AstraZeneca Bayer AG Biogen Inc. Celgene Corporation (a subsidiary of Bristol-Myers Squibb) Eli Lilly and Company F. Hoffmann-La Roche Ltd Gilead Sciences, Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co., Inc. Novartis AG Pfizer Inc. Regeneron Pharmaceuticals, Inc. Sanofi S.A. TakedaPharmaceutical Company Limited Teva Pharmaceutical Industries Ltd. UCB S.A. Vertex Pharmaceuticals Incorporated
Methodology
Related Reports
Some other reports from this category!
Our Clients
